Contraceptive with antimineralcorticoid and antiandrogenenic
activity
V.N. Prilepskaya and L.I. Ostreikova
Research Center of Obstet., Gynec.
and Perinat., Moscow, Russia
Combined oral contraceptive Yarina (Yasmin)
containing 0.03 mg ethinylestradiol and 3 mg new gestagen drospirenon is a novel
stage in hormonal contraception. Drospirenon is a derivative of
17-alpha-spironolacton and in some features is similar to it. Due to unique
antimineralcorticoid and antiandrogene effects the use of Yarina arrests eodema
in an organism and thus improves the tolerance of hormonal contraception.
Objectives Analysis of efficacy and tolerance of oral contraceptive Yarina in
women of reproductive age.
Materials and methods Sixty-eight women, aged 18 to 39 (mean
age 24 +/- 3.2) without any contraindications to hormonal contraception.
Follow-up period was 12 months. All patients were examined with clinical methods
and Pap-smear-test. All women were requested to keep menstrual daybook.
Results
At initial examination 19 patients demonstrated the symptoms of premenstrual
syndrome. Subjective and objective status of patients was assessed according to
specially elaborated questionnaire. All patients were noted to have the signs of
irritation on days 4 – 10 prior to menstrual onset, 4 had depressive status,
headaches, oedema was noted in 15 cases. No patient was registered to conceive
during contraception. Intramenstrual bleedings were found in 2 women, vomiting
in one. Decrease or elimination of premenstrual symptoms were detected in 14 out
of 15 patients.
Conclusion Yarina is highly effective contraceptive. It is
generally well tolerated, achieving good cycle control and having beneficial
effects on acne and other skin-related conditions. There is evidence to suggest
that Yarina has a beneficial effect in the treatment of premenstrual syndrome as
well as having a positive effect on well-being and health-related quality of
life. Overall, Yarina is a promising treatment option for women requiring
contraception.